Filing Flows › Nephros (NEPH) › Guidance & outlook
Nephros (NEPH) guidance and outlook
Nephros' 10-Q filed Nov 5, 2026 makes 16 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- Leveraging VARs has enabled us to rapidly expand our access to target customers with limited sales staff expansion.
- We believe that our VAR relationships have and will continue to facilitate growth in filter sales outside of the medical industry.
- In addition to VARs, we also utilize a direct salesforce that targets key geographic regions throughout the country, while focusing on the hospital and dialysis customers.
- With the recent addition of Total PFAS reduction capability, we also anticipate growing relevance in schools and other federally regulated facilities, where adherence to standards such as the Safe Drinking Water Act is a key consideration.
- CMS guidance directs facilities to align their WMPs with prevailing industry standards, including ASHRAE Standard 188 and the CDC water management toolkit.
- We believe, in time, most commercial buildings will need to follow the basic requirements of ASHRAE-188: create a water management plan, perform routine testing, and establish a plan to treat the building in the event of a positive test.
- As demand for water testing and microbiological filtration grows, we intend to be ready to deploy our expertise and solutions based on our years of experience servicing the medical market.
- During the nine months ended September 30, 2026, we adopted an accounting policy for expected tariff refunds.
- For services where the standalone selling price is not directly observable through historical transactions, we estimate standalone selling price using expected cost-plus margin based on management judgment by considering available data, such as labor cost of providing the services and internal margin objectives which include market and competitive conditions.
- We anticipate that our annual results of operations will be impacted in the foreseeable future by several factors, including market acceptance of our products, expense management, and our progress toward achieving positive operating cash flow.
- Accordingly, we expect that our gross profit margin will continue to face headwinds as a result of current U.S. tariff policy.
- The following table summarizes our liquidity and capital resources as of September 30, 2026 and December 31, 2025 and is intended to supplement the more detailed discussion that follows.
Nephros' latest quarter
Nephros, Q3 2026: revenue $5.6M (+18% year over year), operating margin 8.9%, net earnings $512K, operating cash flow −$150K. The chart follows the revenue to costs, profit and cash.
Questions
What does Nephros expect?
Leveraging VARs has enabled us to rapidly expand our access to target customers with limited sales staff expansion. We believe that our VAR relationships have and will continue to facilitate growth in filter sales outside of the medical industry. In addition to VARs, we also utilize a direct salesforce that targets key geographic regions throughout the country, while focusing on the hospital and dialysis customers.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.